FASL antibody (Biotin)

Catalog No. ABIN2689027

This anti-FASL antibody is a Mouse Monoclonal antibody detecting FASL in WB and FACS. Suitable for Human. This Primary Antibody has been cited in 6+ publications.

Quick Overview for FASL antibody (Biotin) (ABIN2689027)

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This FASL antibody is conjugated to Biotin

Application: Western Blotting (WB), Flow Cytometry (FACS)

Clone: NOK

Product Details anti-FASL Antibody (Biotin)

Brand: BD Pharmingen™

Characteristics: Fas (CD95, APO-1) is a 45 kDa cell surface protein that mediates apoptosis when cross-linked with agonistic anti-Fas antibodies or by Fas ligand (FasL, CD178). Fas belongs to the TNF (Tumor Necrosis Factor)/NGF (Nerve Growth Factor) receptor family, and is expressed in various tissues and cells including the thymus, liver, ovary and lung. CD178 (FasL), a member of the TNF cytokine family, induces apoptosis by binding to Fas, its cell-surface receptor. FasL may exist as either membrane bound or soluble forms and is expressed by activated T and NK cells. FasL may also be constitutively expressed in some immunologically privileged sites, e.g., eye and testis. Fas and FasL play an important role in the induction of apoptosis, and thus regulate a variety of immunological responses. The NOK-1 antibody clone has been reported to recognize human FasL, recognizing both the membrane bound (FasL) and soluble (sFasL) forms. It is reported that the epitope for NOK-1 has been mapped to the COOH-terminus of FasL, at the region implicated in Fas binding. FasL and sFasL have been reported to migrate at reduced molecular weights of 40 and 26 kDa, respectively. However, the molecular weights observed in a particular sample may vary according to FasL and sFasL glycosylation and breakdown patterns as described in the literature. The NOK-1 antibody clone is not recommended for the western blot application. Flow cytometric analysis of human Fas Ligand (FasL). The mouse T cell lymphoma cell line, L5187Y was transfected with human FasL cDNA and treated with a metalloproteinase inhibitor, KB8301 (left panel). KB8301 blocks FasL cleavage resulting in high levels of cell surface FasL. As expected, FasL was not detected in the parental L5187Y cells after KB8301 treatment (right panel). The data was generated using a 2-step procedure with either biotin-labeled, isotype-matched control antibody (dashed line) or biotin-labeled (NOK-1, Cat. No. 556373) (solid line) followed by Streptavidin-PE.

BD Pharmingen™ Biotin Mouse Anti-Human CD178 - Biotin - Clone NOK-1 - Isotype Mouse IgG1 - Reactivity Hu - 0.1 mg

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Mouse T lymphoma cells (L5178Y) expressing human FasL

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: The antibody was conjugated with biotin under optimum conditions, and unreacted biotin was removed.

Storage: 4 °C

Storage Comment: Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

References for anti-FASL antibody (Biotin) (ABIN2689027)

Orlinick, Elkon, Chao: "Separate domains of the human fas ligand dictate self-association and receptor binding." in: The Journal of biological chemistry, Vol. 272, Issue 51, pp. 32221-9, (1998) (PubMed).

Griffith, Ferguson: "The role of FasL-induced apoptosis in immune privilege." in: Immunology today, Vol. 18, Issue 5, pp. 240-4, (1997) (PubMed).

Kayagaki, Kawasaki, Ebata, Ohmoto, Ikeda, Inoue, Yoshino, Okumura, Yagita: "Metalloproteinase-mediated release of human Fas ligand." in: The Journal of experimental medicine, Vol. 182, Issue 6, pp. 1777-83, (1996) (PubMed).

Lynch, Ramsdell, Alderson: "Fas and FasL in the homeostatic regulation of immune responses." in: Immunology today, Vol. 16, Issue 12, pp. 569-74, (1996) (PubMed).

Tanaka, Suda, Takahashi, Nagata: "Expression of the functional soluble form of human fas ligand in activated lymphocytes." in: The EMBO journal, Vol. 14, Issue 6, pp. 1129-35, (1995) (PubMed).

Takahashi, Tanaka, Brannan, Jenkins, Copeland, Suda, Nagata: "Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand." in: Cell, Vol. 76, Issue 6, pp. 969-76, (1994) (PubMed).

Target Details for FASL

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Alternative Name: CD178

Background: Synonyms: Fas Ligand, CD95 Ligand

Pathways: Apoptosis, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity